GlassScriptPhysician profile
Michael Thomas Banning
NPI 1154749539
$5,572.63
in general payments reported to CMS, 2019-2025
27 companies · $1,481 in 2025
The $1,481 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2020: $55.80 · 2021: $55.56 · 2022: $777 · 2023: $1,051 · 2024: $1,493 · 2025: $1,481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,025.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,024.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $821.62 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $646.45 | 2022-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $578.96 | 2020-2025 | |
| Amgen INC. | $471.58 | 2020-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $463.99 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $392.58 | 2023-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $350.99 | 2022-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $349.74 | 2019-2025 | Farxiga |
| Abbott Laboratories | $319.38 | 2022-2024 | Pressurewire, Xience Skypoint |
| Novo Nordisk INC | $257.34 | 2024-2025 | Wegovy, Ozempic |
| Cardiac Dimensions, INC. | $121.94 | 2023 | |
| Chiesi USA, INC. | $115.80 | 2024-2025 | Kengreal |
| Kiniksa Pharmaceuticals International, Plc | $113.76 | 2024 | Arcalyst |
| Cardiva Medical, INC. | $108.00 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Boston Scientific Corporation | $71.03 | 2020-2024 | Bodyguardian, Watchman Flx |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $62.21 | 2024-2025 | (Ck4) Mcot, (Ck7) Extended Holter, Mcot |
| Kestra Medical Technology Services, INC. | $50.75 | 2024 | Assure Wcd |
| Stryker Corporation | $49.24 | 2025 | Flowtriever |
| Edwards Lifesciences Corporation | $37.68 | 2023-2024 | Sapien 3 Ultra Resilia |
| Shockwave Medical, INC | $37.29 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $35.66 | 2023 | Arcalyst |
| Octapharma USA, INC. | $32.57 | 2025 | Balfaxar |
| Abiomed | $22.54 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $19.05 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $15.24 | 2025 | Uptravi |
| Teleflex LLC | $14.48 | 2023 | Guideliner |
| Medtronic, INC. | $12.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Banning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.